Humulin R (Insulin Human (Rdna))

Humulin R is a recombinant human insulin (rDNA) formulated as a clear solution for injection. It contains insulin human as the active ingredient and is supplied in a standard concentration for subcutaneous or intravenous use. Marketed in the European Union as a prescription‑only product, Humulin R belongs to the insulin class of antidiabetic agents and is used to regulate blood glucose in diabetes mellitus treatment management worldwide.

Humulin R is indicated for the control of hyperglycemia in patients with diabetes mellitus, providing rapid‑acting insulin coverage to mimic physiologic secretion after meals.

- Type 1 diabetes mellitus (insulin‑dependent) - Type 2 diabetes mellitus (when diet, oral agents, or other insulins are insufficient) - Management of diabetic ketoacidosis (IV administration) - Peri‑operative glucose control in surgical patients - Adjustment of basal‑bolus regimens for flexible dosing - Use in pregnancy when benefits outweigh risks (if clinically indicated) - Use in pediatric patients with type 1 diabetes under specialist supervision

Adverse reactions to Humulin R may occur; they are categorized by frequency and severity.

Common: - Mild hypoglycemia (sweating, tremor, hunger) - Injection site reactions such as redness, swelling, or itching - Lipodystrophy (localized fat loss or accumulation) - Weight gain associated with improved glycemic control

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures - Allergic reactions including urticaria, angioedema, or anaphylaxis - Hypersensitivity with eosinophilia or serum‑sickness‑like syndrome - Persistent hyperglycemia due to insulin resistance or dosing errors

Before initiating Humulin R, clinicians should evaluate several safety considerations to minimize risk.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review history of hypoglycemia unawareness or previous severe episodes. - Consider pregnancy, lactation, or planning for pregnancy; insulin may be required but risks should be discussed. - Monitor for potential allergic reactions, especially in patients with known insulin or excipient sensitivities. - Adjust dose during periods of illness, stress, or changes in physical activity. - Use caution in elderly patients due to variable glucose tolerance. - Ensure proper storage and handling to maintain product potency.

Humulin R can interact with other medicines; some combinations should be avoided while others require dose adjustments.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose reduction, which may cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low glucose. - High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming insulin effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that also lower glucose; monitor for additive hypoglycemia. - Diuretics that affect electrolyte balance and insulin sensitivity. - ACE inhibitors or ARBs, which may enhance insulin sensitivity and alter glucose control. - Alcohol consumption, which can cause delayed hypoglycemia; advise patient monitoring.